Results 191 to 200 of about 300,304 (238)

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

Internal auditory canal metastasis as the only brain lesion in progressive lung adenocarcinoma: Case report and literature review. [PDF]

Respir Med Case Rep
Boujnah MY, Ben Rejeb M, Mezghani M, Abdessatar G, Kochbati L.   +4 more
europepmc   +1 more source

Targeting KRAS for cancer therapy

British Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia, Ruonan Liu, Tonia A. Adamide, Isis E. Fernandez, Georgios T. Stathopoulos   +4 more
wiley   +1 more source

The role of particle therapy in the treatment of locally recurrent rectal cancer: a systematic review. [PDF]

Radiol Oncol
Perpar A, Georg P, Ermenc AS.
europepmc   +1 more source

Quizartinib Resistance Mutations and Treatment Outcomes in Relapsed or Refractory FLT3‐ITD–Positive AML

Cancer Science, EarlyView.
ABSTRACT Quizartinib is a FMS‐like tyrosine kinase 3 (FLT3) inhibitor indicated for FLT3 internal tandem duplication (FLT3‐ITD)–positive acute myeloid leukemia (AML). We aimed to evaluate quizartinib resistance mechanisms, in addition to efficacy and safety outcomes, in patients with relapsed or refractory FLT3‐ITD–positive AML.
Yuichiro Semba, Toshihiro Miyamoto, Senji Kasahara, Yoshikane Kikushige, Takahiro Maeda, Goichi Yoshimoto, Shuichi Ota, Akio Saito, Yuho Najima, Hiroki Hosoi, Daigo Niiya, Koji Kato, Koji Nagafuji, Takashi Akasaka, Tomohiko Kamimura, Atsushi Takita, Maiko Narahara, Tadashi Toki, Koichi Iwanaga, Koji Yonemoto, Mine Harada, Koichi Akashi   +21 more
wiley   +1 more source

Reirradiation With Proton Therapy Using Hypofractionated Schedules: A Systematic Review of the Literature. [PDF]

Int J Part Ther
Alterio D, Pierini VE, Volpe S, Vincini MG, Zaffaroni M, Ferrari A, Giulia M, Mastroleo F, Andratschke N, Guckenberger M, Kubeš J, Meattini I, Nieder C, van der Linden Y, Petralia G, Orecchia R, Jereczek-Fossa BA.   +16 more
europepmc   +1 more source

Proportion of Screen‐Detected Gastrointestinal Cancers From the National Cancer Registry in Japan

Cancer Science, EarlyView.
Using the data from the Japanese National Cancer Registry, screen‐detected gastrointestinal cancers accounted for roughly 20% of all detected routes. We also found that the proportion of screen‐detected cancers was positively correlated with screening participation rates, supporting screen‐detected cancer proportion as a valuable indicator for ...
Ryuji Okamoto, Yukai Lu, Taisuke Ishii, Tomio Nakayama, Kensuke Shinmura, Tomonori Yano, Motoki Iwasaki   +6 more
wiley   +1 more source

Nordic Society of Paediatric Haematology and Oncology (NOPHO) Radiotherapy Working Group consensus guidelines on radiotherapy for paediatric low-grade gliomas. [PDF]

Acta Oncol
Embring A, Skyttä T, Engellau J, Kerna I, Sendiuliene D, Blomstrand M, Indelicato DJ, Timmermann B, Lassen-Ramshad Y, Magelssen H.   +9 more
europepmc   +1 more source

Advances in Radiotherapy for Neoadjuvant Therapy of Stage III Non‐Small Cell Lung Cancer

Cancer Science, EarlyView.
This review summarizes three neoadjuvant radiotherapy techniques for stage III NSCLC, highlighting SFRT's low‐toxicity dual immune‐tumor control benefits and radioimmunotherapy's superior pathological response to guide precise multimodal treatment. ABSTRACT This review aims to systematically summarize the mechanisms of action, clinical evolution, and ...
Qinrong Mao, Yuanchun Yu, Yan Fang, Shaofeng Zhu, Chengjin Tang, Jing Cai   +5 more
wiley   +1 more source

Thyroid V40 as a potential early predictor of hypothyroidism following hypofractionated locoregional breast radiotherapy. [PDF]

PLoS One
Khalifa M, Soliman M, Omar A, Abouegylah M, Ameen AM, Mohamad YM, Arafat W.   +6 more
europepmc   +1 more source